Page 208 - 2021_07-Haematologica-web

A.J. Unsworth et al. 2014;123(8):e11-22.
38. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102(2):449-461.
39. Bynagari-Settipalli YS, Cornelissen I, Palmer D, et al. Redundancy and interac- tion of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. Arterioscler Thromb Vasc Biol. 2014;34(12):2563-2569.
40. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340-345.
41. Karim ZA, Vemana HP, Alshbool FZ, et al.
Characterization of a novel function-block- ing antibody targeted against the platelet P2Y1 receptor. Arterioscler Thromb Vasc Biol. 2015;35(3):637-644.
42. Hankey GJ, Eikelboom JW. Aspirin resist- ance. Lancet. 2006;367(9510):606-617.
43. Warner TD, Nylander S, Whatling C. Anti- platelet therapy: cyclo-oxygenase inhibi- tion and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011;72(4):619-633.
44. Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol. 2017;177(5):674-683.
45. Antithrombotic Trialists (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
46. XieY,XuK,DaiB,etal.The44kDaPim- 1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. 2006;25(1):70-78.
1978
haematologica | 2021; 106(7)